Drug Administration Schedule

Publication Title: 
Lancet (London, England)

BACKGROUND: The burden of Plasmodium vivax infections has been underappreciated, especially in southeast Asia where chloroquine resistant strains have emerged. Our aim was to compare the safety and efficacy of dihydroartemisinin-piperaquine with that of artemether-lumefantrine in patients with uncomplicated malaria caused by multidrug-resistant P falciparum and P vivax. METHODS: 774 patients in southern Papua, Indonesia, with slide-confirmed malaria were randomly assigned to receive either artemether-lumefantrine or dihydroartemisinin-piperaquine and followed up for at least 42 days.

Author(s): 
Ratcliff, A.
Siswantoro, H.
Kenangalem, E.
Maristela, R.
Wuwung, R. M.
Laihad, F.
Ebsworth, E. P.
Anstey, N. M.
Tjitra, E.
Price, R. N.
Publication Title: 
British Journal of Clinical Pharmacology

AIMS: To describe the time-course of the autoinduction of artemisinin by applying a semi-physiological pharmacokinetic model. METHODS: Plasma concentration-time data from six clinical studies involving oral administration of artemisinin to healthy subjects and malaria patients were included in the analysis. NONMEM was used to apply a semi-physiological model incorporating metabolizing enzymes and a pharmacokinetic model including a separate hepatic compartment. RESULTS: The model described the data well.

Author(s): 
Asimus, Sara
Gordi, Toufigh
Publication Title: 
Antimicrobial Agents and Chemotherapy

Dihydroartemisinin-piperaquine (DHP) is an important new treatment for drug-resistant malaria, although pharmacokinetic studies on the combination are limited. In Papua, Indonesia, we assessed determinants of the therapeutic efficacy of DHP for uncomplicated malaria. Plasma piperaquine concentrations were measured on day 7 and day 28, and the cumulative risk of parasitological failure at day 42 was calculated using survival analysis.

Author(s): 
Price, R. N.
Hasugian, A. R.
Ratcliff, A.
Siswantoro, H.
Purba, H. L. E.
Kenangalem, E.
Lindegardh, N.
Penttinen, P.
Laihad, F.
Ebsworth, E. P.
Anstey, N. M.
Tjitra, E.
Publication Title: 
Antimicrobial Agents and Chemotherapy

The population pharmacokinetics of piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria treated with two different dosage regimens of dihydroartemisinin-piperaquine were characterized. Piperaquine pharmacokinetics in 98 Burmese and Karen patients aged 3 to 55 years were described by a two-compartment disposition model with first-order absorption and interindividual random variability on all parameters and were similar with the three- and four-dose regimens.

Author(s): 
Tarning, J.
Ashley, E. A.
Lindegardh, N.
Stepniewska, K.
Phaiphun, L.
Day, N. P. J.
McGready, R.
Ashton, M.
Nosten, F.
White, N. J.
Publication Title: 
Zhong Xi Yi Jie He Xue Bao = Journal of Chinese Integrative Medicine

OBJECTIVE: To our knowledge, there has been no clinical report of artesunate in the treatment of lung cancer. This study was designed to compare the efficacy and toxicity of artesunate combined with NP (a chemotherapy regimen of vinorelbine and cisplatin) and NP alone in the treatment of advanced non-small cell lung cancer (NSCLC). METHODS: One hundred and twenty cases of advanced NSCLC were randomly divided into simple chemotherapy group (control group, n=60) and combined artesunare with chemotherapy group (trial group, n=60).

Author(s): 
Zhang, Zhu-Yi
Yu, Shi-Qing
Miao, Li-Yun
Huang, Xiao-Ying
Zhang, Xiao-ping
Zhu, Yu-Ping
Xia, Xiao-hong
Li, Dan-Qi
Publication Title: 
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases

OBJECTIVES: Malaria kills approximately 1.5 to 2.7 million people each year. Despite the introduction of artemisinin-based combination therapies (ACTs), the treatment of malaria is hampered by problems such as inadequate efficacy, recrudescence, early re-infection, low patient compliance, and high cost price of drugs.

Author(s): 
Penali, Louis Koné
Jansen, Frans Herwig
Publication Title: 
Tropical medicine & international health: TM & IH

Understanding the optimal treatment of uncomplicated malaria in children is challenging because of the availability of new drugs and the shift to combination therapies. This is a review of the guiding principles for the treatment of uncomplicated malaria, the essential anti-malarial drugs for children, and the treatment regimens currently recommended.

Author(s): 
Deen, Jacqueline L.
von Seidlein, Lorenz
Dondorp, Arjen
Publication Title: 
Tropical medicine & international health: TM & IH

OBJECTIVES: Several products of artesunate plus amodiaquine (AS + AQ) are being deployed in malaria-endemic countries for treating uncomplicated falciparum malaria but dosing accuracy and consequential effects on efficacy and tolerability have not been examined. METHODS: Patients with parasitologically confirmed, uncomplicated falciparum malaria were treated and followed by research teams or local health centre staff in Casamance, Senegal.

Author(s): 
Brasseur, P.
Agnamey, P.
Gaye, O.
Cisse, M.
Badiane, M.
Vaillant, M.
Taylor, W. R. J.
Olliaro, P.
Publication Title: 
Malaria Journal

BACKGROUND: Artemether/lumefantrine (AL) has been adopted as the treatment of choice for uncomplicated malaria in Kenya and other countries in the region. Six-dose artemether/lumefantrine tablets are highly effective and safe for the treatment of infants and children weighing between five and 25 kg with uncomplicated Plasmodium falciparum malaria. However, oral paediatric formulations are urgently needed, as the tablets are difficult to administer to young children, who cannot swallow whole tablets or tolerate the bitter taste of the crushed tablets.

Author(s): 
Juma, Elizabeth A.
Obonyo, Charles O.
Akhwale, Willis S.
Ogutu, Bernhards R.
Publication Title: 
Malaria Journal

BACKGROUND: Artemisinin-based combination therapy (ACT) is recommended as a means of prolonging the effectiveness of first-line malaria treatment regimens. Different brands of mefloquine (MQ) have been reported to be non-bioequivalent; this could result in sub-therapeutic levels of mefloquine with decreased efficacy. In 2002, mefloquine-artesunate (MQ-AS) combination therapy was adopted as the first-line treatment for uncomplicated Plasmodium falciparum malaria in the Amazon region of Peru.

Author(s): 
Gutman, Julie
Green, Michael
Durand, Salomon
Rojas, Ofelia Villalva
Ganguly, Babita
Quezada, Wilmer Marquiño
Utz, Gregory C.
Slutsker, Laurence
Ruebush, Trenton K.
Bacon, David J.

Pages

Subscribe to RSS - Drug Administration Schedule